Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

HUTCHMED (China) Limited - American Depositary Shares (NQ:HCM)

13.82 +0.74 (+5.70%)
Delayed Quote Updated: 10:52 AM EST, Nov 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about HUTCHMED (China) Limited - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
HUTCHMED Announces Regulatory Filings Accepted for Review for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer in Europe and Japan
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Primary Immune Thrombocytopenia
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
Save the Date: HUTCHMED to Host Expert Insights Event on Recent Savolitinib Clinical Data in Non-Small Cell Lung Cancer
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Highlights SANOVO Phase III Data for ORPATHYS® plus TAGRISSO® in First-Line EGFR-Mutated Lung Cancer Presented at ESMO Congress 2026
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Highlights SAFFRON Global Phase III Data Presented at ESMO Congress 2026 and Simultaneously Published in The New England Journal of Medicine
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Announces Closing of KRAS-EGFR-Antibody Conjugate Therapy License to GSK Outside China
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Announces Submission of US NDA for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors
First-in-class KRAS-payload leveraging synchronized EGFR inhibition 
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2026
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Lands GSK Deal Worth Up to $1.3B for KRAS-EGFR Cancer Therapy ↗
HUTCHMED (NASDAQ:HCM) said it has entered a co-development and licensing agreement with GSK for ex-China rights to HMPL-A830, a preclinical KRAS-EGFR antibody-targeted therapy conjugate, or ATTC. The... 
Via MarketBeat
News headline image
HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Announces SANOVO Trial Demonstrated Significant Progression-Free Survival Benefit of ORPATHYS® Plus TAGRISSO® in Treatment-Naïve Patients with MET-Overexpressing EGFR-mutated Lung Cancer in China
Findings build on the established success of the global SAFFRON and China SACHI trials, extending the clinical value of the all-oral combination into the first-line setting 
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Announces NMPA Approval for ATLED® (Fanregratinib) for the Treatment of Patients with FGFR2-Fusion/Rearrangement Intrahepatic Cholangiocarcinoma
Novel, highly potent oral selective FGFR 1/2/3 inhibitor approved for patients with advanced FGFR2-altered intrahepatic cholangiocarcinoma in China 
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Announces ORPATHYS® Plus TAGRISSO® Demonstrated Statistically Significant and Clinically Meaningful Improvements in Progression-Free and Overall Survival in MET-Driven EGFR-Mutated Lung Cancer After Progression on TAGRISSO®
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED H1 Earnings Call Highlights ↗
HUTCHMED (NASDAQ:HCM) reported first-half 2026 oncology revenue of $162 million, including $121 million in product revenue, as growth in China and expanding international sales of FRUZAQLA supported... 
Via MarketBeat
Topics Earnings
News headline image
HUTCHMED Reports 2026 Interim Results
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Announces NMPA Approval for ORPATHYS® for the treatment of Gastric Cancer Patients with MET Amplification
First selective MET inhibitor approved for patients with MET-amplified advanced gastric cancer or gastroesophageal junction adenocarcinoma in China 
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED to Announce 2026 Half-Year Financial Results
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Highlights Pivotal Phase II Data for Fanregratinib in Intrahepatic Cholangiocarcinoma Presented at ESMO Gastrointestinal Cancers Congress 2026
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Highlights Sovleplenib ESLIM-02 Phase III Data in Warm Antibody Autoimmune Hemolytic Anemia Presented at EHA 2026 Congress
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Highlights Clinical Data to be Presented at the 2026 ASCO Annual Meeting
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED and Innovent Jointly Announce NMPA Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma
Reduced risk of disease progression or death by 63%, with median PFS of 22.2 months in the FRUSICA-2 registration study 
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
HUTCHMED Announces NDA Acceptance in China with Priority Review Status and Breakthrough Designation for Sovleplenib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on April 28, 2026
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2026
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Initiates Phase III Trial of HMPL-760 in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma in China
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Announces Update on Licensed Oncology Product TAZVERIK® in China
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
Intended Retirement of Independent Non-executive Director and changes of composition of board committees
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Reports 2025 Full Year Results and Business Updates
From HUTCHMED (China) Limited
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.